Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-finding study of setrusumab in adult osteogenesis imperfecta
2016-005096-27Phase 2Completed
- Sponsor
- Mereo BioPharma
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of setrusumab in osteogenesis imperfecta (OI) (2 arms), sponsored by Mereo BioPharma. Primary endpoints: Radial trabecular volumetric bone mineral density at 12 months and Bone strength by finite element analysis at 12 months. Started Mar 2017; status: completed.
02
Drugs
setrusumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on 2016-005096-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005096-27.